Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease (original) (raw)

• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.
  Article PubMed Google Scholar
• Tahrani AA, Bailey CJ, Del Prato S, et al. Management of type 2 diabetes: new and future developments in treatment. Lancet. 2011;378(9786):182–97.
  Article CAS PubMed Google Scholar
• Bonnet F, Scheen AJ. SGLT-2 inhibitors: an opportunity to renew our therapeutic strategy for type 2 diabetes ? Diabetes Metab. 2014;40(Suppl):S1–3.
  Article PubMed Google Scholar
• Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010;70(4):377–85.
  Article CAS PubMed Google Scholar
• Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013;1(2):140–51.
  Article CAS PubMed Google Scholar
• Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2014;104(3):297–322.
  Article CAS PubMed Google Scholar
• Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011;32(2):63–71.
  Article CAS PubMed Google Scholar
• Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32(4):515–31.
  Article CAS PubMed Google Scholar
• Scheen AJ, Paquot N. Metabolic effects SGLT2 inhibitors beyond increased glucosuria: a review of clinical evidence. Diabetes Metab. 2014;40(Suppl):S4–11.
  Article CAS PubMed Google Scholar
• Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262–74.
  Article PubMed Google Scholar
• Berhan A, Barker A. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocr Disord. 2013;13(1):58.
  Article PubMed Central PubMed Google Scholar
• Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335–80.
  Article CAS PubMed Central PubMed Google Scholar
• Scheen AJ. Pharmacodynamics, efficacy and safety of SGLT2 inhibitors for the treatment of type 2 diabetes. Drugs. 2015;75(1):33–59.
  Article PubMed Google Scholar
• Scheen AJ. Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol. 2014;10(5):647–63.
  Article CAS PubMed Google Scholar
• Scheen AJ. Drug-drug interactions with SGLT-2 inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes. Clin Pharmacokinet. 2014;53(4):295–304.
  Article CAS PubMed Google Scholar
• Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(17):2289–312.
  Article CAS PubMed Google Scholar
• Kasichayanula S, Liu X, Lacreta F, et al. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014;53(1):17–27.
  Article CAS PubMed Google Scholar
• Plosker GL. Dapagliflozin: a review of its use in patients with type 2 diabetes. Drugs. 2014;74(18):2191–209.
  Article CAS PubMed Google Scholar
• Elkinson S, Scott LJ. Canagliflozin: first global approval. Drugs. 2013;73(9):979–88.
  Article CAS PubMed Google Scholar
• Lamos EM, Younk LM, Davis SN. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013;9(6):763–75.
  Article CAS PubMed Google Scholar
• Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74(7):807–24.
  Article CAS PubMed Google Scholar
• Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53(3):213–25.
  Article CAS PubMed Central PubMed Google Scholar
• Seman L, Macha S, Nehmiz G, et al. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Devel. 2013;2(2):152–61.
  Article CAS Google Scholar
• Scott LJ. Empagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs 2014 (Epub 2014/10/03).
• Poole RM, Dungo RT. Ipragliflozin: first global approval. Drugs. 2014;74(5):611–7.
  Article CAS PubMed Google Scholar
• Markham A, Elkinson S. Luseogliflozin: first global approval. Drugs. 2014;74(8):945–50.
  Article CAS PubMed Google Scholar
• Poole RM, Prossler JE. Tofogliflozin: first global approval. Drugs. 2014;74(8):939–44.
  Article CAS PubMed Google Scholar
• Scheen AJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol. 2013;9(5):529–50.
  Article CAS PubMed Google Scholar
• Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962–71.
  Article CAS PubMed Central PubMed Google Scholar
• Maliha G, Townsend RR. SGLT2 inhibitors: their potential reduction in blood pressure. J Am Soc Hypertens. 2015;9(1):48–53.
  Article CAS PubMed Google Scholar
• Vallon V, Thomson SC. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol. 2012;74:351–75.
  Article CAS PubMed Google Scholar
• De Nicola L, Gabbai FB, Liberti ME, et al. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis. 2014;64(1):16–24.
  Article PubMed Google Scholar
• Stanton RC. Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease? Circulation. 2014;129(5):542–4.
  Article PubMed Google Scholar
• European Medicines Agency. Assessment report. Forxiga (dapagliflozin). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002322/WC500136024.pdf. Accessed 2 Mar 2015.
• European Medicines Agency. Assessment report. Canagliflozin. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002649/WC500156456.pdf. Accessed 2 Mar 2015.
• European Medicines Agency. Assessment report: Jardiance. International non-proprietary name: empagliflozin. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002677/WC500168592.pdf. Accessed 2 Mar 2015.
• Kasichayanula S, Liu X, Pe Benito M, et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013;76(3):432–44.
  Article CAS PubMed Central PubMed Google Scholar
• Ptaszynska A, Mansfield T, Apanovitch AM, et al. Dapagliflozin, selective SGLT2 inhibitor, does not increase risk of fractures. Diabetes. 2014;63(Suppl 1):A282 (abstract 1085-P).
• Ptaszynska A, Johnsson KM, Parikh SJ, et al. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf. 2014;37(10):815–29.
  Article CAS PubMed Google Scholar
• Ptaszynska A, Mansfield T, Johnsson E, et al. Long-term renal safety with dapagliflozin treatment. Diabetologia. 2014;57(Suppl 1):S22 (abstract 798).
• Johnsson E, Johnsson KM, Mansfield TA, et al. Diuresis-related safety and tolerability of dapagliflozin in type 2 diabetes mellitus over 24 weeks. Diabetologia. 2014;57(Suppl 1):S323 (abstract 800).
• Yavin Y, Mansfield TA, Ptaszynska A, et al. Hyperkalemia incidence with the SGLT2 inhibitor dapagliflozin. Diabetes. 2014;63(Suppl 1):A282 (abstract 1086-P).
• Lambers Heerspink HJ, de Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853–62.
• Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8(5):330–9.
  Article CAS PubMed Google Scholar
• Thomas MC. Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab. 2014;5(3):53–61.
  Article CAS PubMed Central PubMed Google Scholar
• Devineni D, Curtin CR, Marbury TC, et al. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Ther. 2015. doi:10.1016/j.clinthera.2014.12.013 (Epub ahead of print).
• Inagaki N, Kondo K, Yoshinari T, et al. Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment. Clin Drug Investig. 2014;34(10):731–42.
  Article CAS PubMed Central PubMed Google Scholar
• Devineni D, Vaccaro N, Polidori D, et al. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Clin Ther. 2014;36(5):698–710.
  Article CAS PubMed Google Scholar
• Roussel R, de Zeeuw D, Law G, et al. Efficacy and safety of canagliflozin (CANA) in patients with type 2 diabetes mellitus (T2DM) who progressed to stage 3A chronic kidney disease during treatment (abstract). Diabetologia. 2014;57(Suppl 1):S322–3 (abstract 799).
• Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15(5):463–73.
• Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16(10):1016–27.
  Article CAS PubMed Google Scholar
• Yamout H, Perkovic V, Davies M, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014;40(1):64–74.
  Article CAS PubMed Google Scholar
• Khurana M, Vaidyanathan J, Marathe A, et al. Canagliflozin use in patients with renal impairment: utility of quantitative clinical pharmacology analyses in dose optimization. J Clin Pharmacol. 2015. doi:10.1002/jcph.466. (Epub ahead of print).
• Macha S, Mattheus M, Halabi A, et al. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab. 2014;16(3):215–22.
  Article CAS PubMed Google Scholar
• Sarashina A, Ueki K, Sasaki T, et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus. Clin Ther. 2014;36(11):1606–15.
  Article CAS PubMed Google Scholar
• Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(5):369–84.
  Article CAS PubMed Google Scholar
• Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38(3):420–8.
  Article CAS PubMed Google Scholar
• Cherney D, von Eynatten M, Lund SS, et al. Sodium glucose transporter 2 inhibition with empagliflozin reduces microalbuminuria in patients with type 2 diabetes (abstract). Diabetologia. 2014;57(Suppl 1):S333 (abstract 823).
• Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587–97.
  Article CAS PubMed Google Scholar
• Ridderstrale M, Svaerd R, Zeller C, et al. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovasc Diabetol. 2013;12(1):129.
  Article PubMed Central PubMed Google Scholar
• Kadokura T, Zhang W, Krauwinkel W, et al. Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. Clin Pharmacokinet. 2014;53(11):975–88.
  Article CAS PubMed Google Scholar
• Ferrannini E, Veltkamp SA, Smulders RA, et al. Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care. 2013;36(5):1260–5.
  Article CAS PubMed Central PubMed Google Scholar
• Kashiwagi A, Takahashi H, Ishikawa H, et al. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long-Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study. Diabetes Obes Metab. 2015;17(2):152–60.
  Article CAS PubMed Google Scholar
• Zell M, Husser C, Kuhlmann O, et al. Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans. Xenobiotica. 2014;44(4):369–78.
  Article CAS PubMed Google Scholar
• Schwab D, Portron A, Backholer Z, et al. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans. Clin Pharmacokinet. 2013;52(6):463–73.
  Article CAS PubMed Google Scholar
• Schwab D, Portron A, Fukushima Y, et al. Tofogliflozin a selective SGLT2 inhibitor exhibits highly favourable drug properties for use in patients with renal impairment and for combination with other medicines. Diabetologia. 2012;55(Suppl 1):S316 (abstract 767).
  Google Scholar
• Sasaki T, Seino Y, Fukatsu A, et al. Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial. Adv Ther. 2014;31(3):345–61.
  Article CAS PubMed Central PubMed Google Scholar
• Haneda M, Seino Y, Inagaki N, et al. Efficacy and safety of luseogliflozin in various levels of renal function in Japanese patients with type 2 diabetes mellitus: analysis of pooled data from long-term phase 3 trials. Diabetes. 2014;63(Suppl 1):A267 (abstract 1035-P).
• Miao Z, Nucci G, Amin N, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013;41(2):445–56.
  Article CAS PubMed Google Scholar
• Kapur A, O’Connor-Semmes R, Hussey EK, et al. First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol. 2013;14:26.
  Article CAS PubMed Central PubMed Google Scholar